Regulatory Pathway for Achaogen Looks Better; Is It Aimed At Viable Commercial Market?
This article was originally published in RPM Report
Executive Summary
With the FDA bottleneck for new anti-infectives showing signs of improvement, the next concern is whether providers will pay high premiums for new anti-infectives and the related challenge of finding the right patients to make high-cost treatments make sense.